Communiqués CNS Pharmaceuticals, Inc.

Actions

CNSP

US18978H5081

Recherche biotechnologique et médicale

Temps Différé Nasdaq 17:29:08 07/10/2026			Varia. 5j.	Varia. 1 janv.
5,440 ^USD	+2,61%		+2,64%	+3,62%

30/09	Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call
12/08	CNS Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

01/09	CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth	AQ
27/08	CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference	AQ
12/08	CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation	AQ
08/06	CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment	AQ
14/05	CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress	AQ
04/05	CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing	AQ
17/12	CNS Pharmaceuticals : Announces CEO Transition	PU
17/11	CNS Pharmaceuticals : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
10/11	CNS Pharmaceuticals : Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting	PU
28/08/25	CNS Pharmaceuticals, Inc. - IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.	AQ
27/08/25	IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.	AQ
18/08/25	CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ
15/08/25	CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series, Biotech, MedTech	AQ
18/07/25	CNS Pharmaceuticals : JTC Team Announces Participating Line Up for the Virtual Investor What's Your Story Summer Spotlight On Demand Conference	PU
25/06/25	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287	AQ
01/04/25	CNS Pharmaceuticals Reports Full Year 2024 Financial Results	AQ
25/03/25	CNS Pharmaceuticals : Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme	PU
25/03/25	CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme	AQ
18/02/25	CNS Pharmaceuticals : to Present at 6th Glioblastoma Drug Development Summit	PU
26/11/24	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV after Failure of Standard First Line Therapy	AQ
18/11/24	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results	AQ
15/11/24	CNS Pharmaceuticals : Quarterly Report for Quarter Ending September, 30, 2024 (Form 10-Q)	PU
04/11/24	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
28/10/24	Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG	AQ
24/10/24	CNS Pharmaceuticals : Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules Form 8 K	PU